Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 10.97 is 37% below its 5-year average of 17.45, near the low end of its 5-year range (9.85–31.70).
As of the fiscal period ended Tuesday, June 30, 2026. 19.02% below its 12-month average of 13.55.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 10.97.
CURRENT RATIO
10.97
CURRENT RATIO AVG TTM
13.55
CURRENT RATIO AVG 3Y
13.69
CURRENT RATIO AVG 5Y
17.45
CURRENT RATIO AVG 10Y
13.30
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-19.02%
CURRENT VS 3Y AVG
-19.83%
CURRENT VS 5Y AVG
-37.12%
CURRENT VS 10Y AVG
-17.52%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.76
median of 873 covered companies
CURRENT VS SECTOR MEDIAN
+191.84%
vs the sector median at left
Protara Therapeutics, Inc.
Market Cap
$143.60M
Current Ratio
10.97
TTM Avg
13.55
3Y Avg
13.69
5Y Avg
17.45
Market Cap
$143.84M
Current Ratio
1.23
TTM Avg
1.14
3Y Avg
1.35
5Y Avg
4.96
Market Cap
$146.27M
Current Ratio
3.96
TTM Avg
1.88
3Y Avg
1.73
5Y Avg
2.58
Market Cap
$146.62M
Current Ratio
2.47
TTM Avg
5.27
3Y Avg
13.16
5Y Avg
16.37
Market Cap
$139.04M
Current Ratio
19.47
TTM Avg
11.39
3Y Avg
11.91
5Y Avg
15.23
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | $143.60M | 10.97 | 13.55 | 13.69 | 17.45 |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $143.84M | 1.23 | 1.14 | 1.35 | 4.96 |
| Nyxoah S.A. (NYXH)vs › | $143.10M | 2.38 | 2.90 | 4.31 | 7.34 |
| Fortress Biotech, Inc. (FBIOP)vs › | $146.27M | 3.96 | 1.88 | 1.73 | 2.58 |
| Codexis, Inc. (CDXS)vs › | $146.28M | 3.06 | 4.00 | 3.48 | 4.36 |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.62M | 2.47 | 5.27 | 13.16 | 16.37 |
| Sutro Biopharma, Inc. (STRO)vs › | $139.84M | 3.32 | 2.30 | 3.60 | 5.41 |
| Alpha Cognition Inc (ACOG)vs › | $139.47M | 9.03 | 11.82 | 6.24 | 5.64 |
| Immuneering Corporation (IMRX)vs › | $139.04M | 19.47 | 11.39 | 11.91 | 15.23 |
| Anavex Life Sciences Corp. (AVXL)vs › | $148.27M | 15.62 | 10.23 | 11.93 | 11.24 |
Current Ratio
10.97
Quick Ratio
10.97
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 10.97 |
| 2026-03-31 | 15.69 |
| 2025-12-31 | 14.58 |
| 2025-09-30 | 13.69 |
| 2025-06-30 | 12.82 |
| 2025-03-31 | 18.03 |
| 2024-12-31 | 15.71 |
| 2024-09-30 | 9.85 |
| 2024-06-30 | 16.33 |
| 2024-03-31 | 10.53 |
| 2023-12-31 | 11.17 |
| 2023-09-30 | 11.49 |
| 2023-06-30 | 17.09 |
| 2023-03-31 | 14.76 |
| 2022-12-31 | 15.01 |
| 2022-09-30 | 26.59 |
| 2022-06-30 | 28.94 |
| 2022-03-31 | 31.70 |
| 2021-12-31 | 21.66 |
| 2021-09-30 | 25.95 |
| 2021-06-30 | 23.94 |
| 2021-03-31 | 26.47 |
| 2020-12-31 | 58.13 |
| 2020-09-30 | 43.00 |
| 2020-06-30 | 9.53 |
| 2020-03-31 | 7.99 |
| 2019-12-31 | 11.96 |
| 2019-09-30 | 56.78 |
| 2019-06-30 | 5.41 |
| 2019-03-31 | 1.65 |
| 2018-12-31 | 7.55 |
| 2018-09-30 | 10.69 |
| 2018-06-30 | 12.34 |
| 2018-03-31 | 4.22 |
| 2017-12-31 | 4.71 |
| 2017-09-30 | 5.28 |
| 2017-06-30 | 7.98 |
| 2017-03-31 | 11.72 |
| 2016-12-31 | 8.42 |
| 2016-09-30 | 9.98 |
| 2016-06-30 | 11.58 |
| 2016-03-31 | 16.84 |
| 2015-12-31 | 16.13 |
| 2015-09-30 | 22.52 |
| 2015-06-30 | 27.36 |
| 2015-03-31 | 30.70 |
| 2014-12-31 | 36.15 |
| 2014-09-30 | 8.25 |
